Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(50.0%)
N/A
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 3(2)
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07401329Completed

Early and Late Neutrophil CD64 and Monocyte HLA-DR as Biomarkers for Septic Shock

Role: lead

NCT07191470Not ApplicableCompleted

Safety and Efficacy of Inhaled Sedation in Management of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Role: lead

NCT06377397Phase 3Not Yet Recruiting

Selective Antibiotics When Symptoms Develop Versus Universal Antibiotics for Preterm Neonates

Role: collaborator

NCT03280147Phase 3Completed

7 Days Versus 14 Days of Antibiotics for Neonatal Sepsis

Role: collaborator

NCT02330432Phase 2Completed

Mycobacterium w in Patients With Severe Sepsis

Role: collaborator

All 5 trials loaded